Chromosome translocations in multiple myeloma
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3' enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 40% of multiple myeloma is characterized by the presence of trisomies in the neoplastic plasma cells (hyperdiploid multiple myeloma), while most of the rest have a translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 (IgH translocated multiple myeloma).38–41”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [39]
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,774
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,900
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Anderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Cellular Origin of Human B-Cell Lymphomas
Küppers, R., Klein, U., Hansmann, M.-L., & Rajewsky, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412007 · Cited by 715
The Proto-Oncogene c-maf Is Responsible for Tissue-Specific Expression of Interleukin-4
Ho, I.-C., Hodge, M. R., Rooney, J. W., & Glimcher, L. H. (1996) · Cell · doi:10.1016/s0092-8674(00)81299-4 · Cited by 667
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637 · cited 2×
“…of conventional cytogenetics, SKY analyses, metaphase FISH analyses, isolation of molecular clones, and RT±PCR assays (Bergsagel et al., 1996; Chesi et al., 1997, 1998a; Gabrea et al., 1999; Shaughnessy et al., 2001; Shou et al., 2000; Kuehl, 2001, unpublished results), we have identi®ed at…”
BackgroundSelf-citationChesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 572
Self-citationDNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation
Difilippantonio, M. J., Zhu, J., Chen, H. T., Meffre, E., Nussenzweig, M. C., Max, E. E., Ried, T., & Nussenzweig, A. (2000) · Nature · doi:10.1038/35006670 · Cited by 547
Research works printed but not linked: 1
- Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK . 2000 SEER Cancer Statistics Review, 1973–1997 National Cancer Institute: Bethesda
Cited by
Items 101–200 of 545
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 84
Shi, Y., Frost, P., Hoang, B. Q., Benavides, A., Sharma, S., Gera, J., & Lichtenstein, A. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1066 · Cited by 83
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Yang, W., & Lin, S.-F. (2015) · BioMed Research International · doi:10.1155/2015/341430 · Cited by 84
Testing mutual exclusivity of ETS rearranged prostate cancer
Svensson, M. A., Lafargue, C. J., MacDonald, T. Y., Pflueger, D., Kitabayashi, N., Santa-Cruz, A. M., Garsha, K. E., Sathyanarayana, U. G., Riley, J., Yun, C. S., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.179 · Cited by 81
Alagpulinsa, D. A., Ayyadevara, S., Yaccoby, S., & Shmookler Reis, R. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0660 · Cited by 74
The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor
Lemaire, M., Deleu, S., Bruyne, E. D., Valckenborgh, E. V., Menu, E., & Vanderkerken, K. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00002-5 · Cited by 80
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
Chang, H., Stewart, A. K., Qi, X. Y., Li, Z., Yi, Q. L., & Trudel, S. (2005) · Blood · doi:10.1182/blood-2005-01-0033 · Cited by 79
Unniraman, S., Zhou, S., & Schatz, D. G. (2004) · Nature Immunology · doi:10.1038/ni1127 · Cited by 79
Clinical value of molecular subtyping multiple myeloma using gene expression profiling
Weinhold, N., Heuck, C. J., Rosenthal, A., Thanendrarajan, S., Stein, C. K., Van Rhee, F., Zangari, M., Hoering, A., Tian, E., Davies, F. E., et al. (2016) · Leukemia · doi:10.1038/leu.2015.309 · Cited by 70
G-Rich Proto-Oncogenes Are Targeted for Genomic Instability in B-Cell Lymphomas
Duquette, M. L., Huber, M. D., & Maizels, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2419 · Cited by 77
Anguiano, A., Tuchman, S. A., Acharya, C. R., Salter, K. H., Gasparetto, C., Zhan, F., Dhodapkar, M. V., Nevins, J. R., Barlogie, B., Shaughnessy, J. D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1916 · Cited by 78
Suzuki, A., Iida, S., Kato-Uranishi, M., Tajima, E., Zhan, F., Hanamura, I., Huang, Y., Ogura, T., Takahashi, S., Ueda, R., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208844 · Cited by 77
Analysis of PTEN deletions and mutations in multiple myeloma
Chang, H., Xiao, Q., Claudio, J. O., Zhuang, L., Patterson, B. J., & Stewart, A. K. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.07.008 · Cited by 76
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Johnsen, H. E., Bøgsted, M., Schmitz, A., Bødker, J. S., El‐Galaly, T. C., Johansen, P., Valent, P., Zojer, N., Valckenborgh, E. V., Vanderkerken, K., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.138826 · Cited by 75
Epidemiology and outcomes research for MGUS, myeloma and amyloidosis
Sirohi, B., & Powles, R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.065 · Cited by 74
B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies
Vaque, J. P., Martínez, N., Batlle‐López, A., Perez, C., Montes‐Moreno, S., Sánchez‐Beato, M., & Piris, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.096248 · Cited by 71
Xin, X., Abrams, T. J., Hollenbach, P. W., Rendahl, K. G., Tang, Y., Oei, Y. A., Embry, M. G., Swinarski, D., Garrett, E. N., Pryer, N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0957 · Cited by 71
Cytogenetics and molecular cytogenetics in multiple myeloma
Liebisch, P., & Döhner, H. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.12.028 · Cited by 70
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Kyle, R. A., & Rajkumar, S. V. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0047-9 · Cited by 61
DNA methylation of microRNA genes in multiple myeloma
Wong, K. Y., Huang, X., & Chim, C. S. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs212 · Cited by 69
Chang, H., Qi, X. Y., Samiee, S., Yi, Q., Chen, C., Trudel, S., Mikhael, J. R., Reece, D. E., & Stewart, A. K. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705131 · Cited by 67
Distinguishing primary and secondary translocations in multiple myeloma
Gabrea, A., Bergsagel, P. L., & Kuehl, W. M. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.012 · Cited by 65
Self-citationMonoclonal gammopathy of undetermined significance and smoldering multiple myeloma
Rajkumar, S. V., Lacy, M. Q., & Kyle, R. A. (2007) · Blood Reviews · doi:10.1016/j.blre.2007.01.002 · Cited by 65
Boersma‐Vreugdenhil, G. R., Kuipers, J., Van Stralen, E., Peeters, T., Michaux, L., Hagemeijer, A., Pearson, P. L., Clevers, H. C., & Bast, B. J. E. G. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05050.x · Cited by 54
Multiple Myeloma Regression Mediated by Bruceantin
Cuendet, M., Christov, K. T., Lantvit, D. D., Deng, Y., Hedayat, S., Helson, L., McChesney, J. D., & Pezzuto, J. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0362-3 · Cited by 62
Cook, J. R., Hsi, E. D., Worley, S. E., Tubbs, R. R., & Hussein, M. A. (2006) · American Journal of Clinical Pathology · doi:10.1309/bdr959tt4ju6388c · Cited by 62
Holien, T., Våtsveen, T. K., Hella, H., Rampa, C., Brede, G., Grøseth, L. A. G., Rekvig, M., Børset, M., Standal, T., Waage, A., et al. (2011) · Leukemia · doi:10.1038/leu.2011.263 · Cited by 59
VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine
Yang, E. V., Donovan, E. L., Benson, D. M., & Glaser, R. (2007) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2007.09.010 · Cited by 58
Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus
Klatt, E. C., & Kumar, V. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4930-2.00013-x · Cited by 58
Sepúlveda, M. A., Garrett, F. E., Price‐Whelan, A., & Birshtein, B. K. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.09.006 · Cited by 58
Jia, Y., Zhou, J., Tan, T. K., Chung, T.-H., Chen, Y., Chooi, J.-Y., Sanda, T., Fullwood, M. J., Xiong, S., Toh, S. H. M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0921 · Cited by 57
Qazilbash, M. H., Saliba, R. M., Ahmed, B., Parikh, G. C., Mendoza, F. L., Ashraf, N., Hosing, C. M., Flosser, T., Weber, D. M., Wang, M. L., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.05.014 · Cited by 57
Simeone, A., Ekmekçioglu, S., Broemeling, L. D., Grimm, E. A., & Tari, A. M. (2002) · PubMed · Cited by 57
Rasmussen, T., Haaber, J., Dahl, I. M., Knudsen, L. M., Kerndrup, G. B., Lodahl, M., Johnsen, H. E., & Kuehl, M. W. (2010) · Haematologica · doi:10.3324/haematol.2010.024778 · Cited by 55
MafA has strong cell transforming ability but is a weak transactivator
Nishizawa, M., Kataoka, K., & Vogt, P. K. (2003) · Oncogene · doi:10.1038/sj.onc.1206526 · Cited by 54
Magrangeas, F., Cormier, M.-L., Descamps, G., Gouy, N., Lodé, L., Mellerin, M., Harousseau, J., Bataille, R., Minvielle, S., Avet‐Loiseau, H., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2501 · Cited by 54
A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma
Dring, A. M., Davies, F. E., Fenton, J. A. L., Roddam, P. L., Scott, K. E., Gonzalez, D., Rollinson, S. J., Rawstron, A. C., Rees‐Unwin, K. S., Li, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0467 · Cited by 54
Fabris, S., Agnelli, L., Mattioli, M., Baldini, L., Ronchetti, D., Morabito, F., Verdelli, D., Nobili, L., Intini, D., Callea, V., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20123 · Cited by 53
Peng, B. H., Hodge, D. R., Thomas, S. B., Cherry, J. M., Munroe, D. J., Pompéia, C., Xiao, W., & Farrar, W. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412566200 · Cited by 53
Chang, H., Samiee, S., & Yi, Q. L. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500272549 · Cited by 52
Reynaud, S., Delpy, L., Fleury, L., Dougier, H.-L., Sirac, C., & Cogné, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6176 · Cited by 51
The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding
Ferguson, B. W., Gao, X., Żelazowski, M. J., Lee, J., Jeter, C. R., Abba, M. C., & Aldaz, C. M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-593 · Cited by 50
Szabo, A. G., Gang, A. O., Pedersen, M. Ø., Poulsen, T. S., Klausen, T. W., & Nørgaard, P. H. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1187275 · Cited by 50
Onwuazor, O. N., Wen, X., Wang, D. Y., Zhuang, L., Masih‐Khan, E., Claudio, J., Barlogie, B., Shaughnessy, J. D., & Stewart, A. K. (2003) · Blood · doi:10.1182/blood-2003-04-1204 · Cited by 50
The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia
Dyer, M. J. S., & Oscier, D. (2002) · Leukemia · doi:10.1038/sj.leu.2402528 · Cited by 49
Ansari‐Pour, N., Samur, M., Flynt, E., Gooding, S., Towfic, F., Stong, N., Estévez, M. O., Mavrommatis, K., Walker, B. A., Morgan, G. J., et al. (2022) · Blood · doi:10.1182/blood.2022017010 · Cited by 47
Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes
Mohamed, A. N., Bentley, G., Bonnett, M. L., Zonder, J., & Al-Katib, A. M. (2007) · American Journal of Hematology · doi:10.1002/ajh.20998 · Cited by 47
Chen, J., Williams, I. R., Lee, B. H., Duclos, N., Huntly, B. J. P., Donoghue, D. J., & Gilliland, D. G. (2005) · Blood · doi:10.1182/blood-2004-09-3686 · Cited by 47
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 48
Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Forster, S., Radpour, R., & Ochsenbein, A. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243997 · Cited by 45
WWOX, the FRA16D gene: A target of and a contributor to genomic instability
Hussain, T., Liu, B., Schrock, M. S., Williams, T. M., & Aldaz, C. M. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22693 · Cited by 45
Cheriyath, V., Kuhns, M. A., Kalaycio, M. E., & Borden, E. C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.42 · Cited by 45
Genomic instability in multiple myeloma: mechanisms and therapeutic implications
Neri, P. E., & Bahlis, N. J. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.814637 · Cited by 45
Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results
Harrison, C. J., Mazzullo, H., Cheung, K. L., Gerrard, G., Jalali, G. R., Mehta, A. B., Osier, D., & Orchard, K. H. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04172.x · Cited by 45
IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells
Shi, Y., Frost, P., Hoang, B. Q., Benavides, A., Gera, J., & Lichtenstein, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153221 · Cited by 44
Epigenetic Function of Activation-Induced Cytidine Deaminase and Its Link to Lymphomagenesis
Domínguez, P. M., & Shaknovich, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00642 · Cited by 44
Extramedullary Multiple Myeloma: Challenges and Opportunities
Ho, M., Paruzzo, L., Minehart, J. C., Nabar, N. R., Noll, J. H., Luo, T., Garfall, A. L., & Zanwar, S. (2025) · Current Oncology · doi:10.3390/curroncol32030182 · Cited by 44
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 43
Targeting signalling pathways for the treatment of multiple myeloma
Podar, K., Hideshima, T., Chauhan, D., & Anderson, K. C. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.359 · Cited by 43
Stewart, P., Thompson, A., Santra, M., Barlogie, B., Lappin, T. R. J., & Shaughnessy, J. D. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04996.x · Cited by 43
DNA Methylation of Tumor Suppressor Protein-Coding and Non-Coding Genes in Multiple Myeloma
Wong, K. Y., & Chim, C. S. (2015) · Epigenomics · doi:10.2217/epi.15.57 · Cited by 42
Asimakopoulos, F. A., Hope, C. L., Johnson, M. G., Pagenkopf, A. C., Gromek, K., & Nagel, B. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr1116-468r · Cited by 42
Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance
Rajkumar, S. V. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1575 · Cited by 43
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma
Tshuikina, M., Jernberg‐Wiklund, H., Nilsson, K., & Oberg, F. G. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.08.001 · Cited by 42
IL-6-independent expression of Mcl-1 in human multiple myeloma
Zhang, B., Potyagaylo, V., & Fenton, R. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206358 · Cited by 42
Chromothripsis as a pathogenic driver of multiple myeloma
Maura, F., Boyle, E. M., Rustad, E. H., Ashby, C., Kaminetzky, D., Bruno, B., Braunstein, M. J., Bauer, M., Blaney, P., Wang, Y., et al. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.04.014 · Cited by 41
Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization
Chang, H., Sloan, S., Li, D., & Patterson, B. J. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2004.05.004 · Cited by 41
Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
Caers, J., Menu, E., Raeve, H. D., LePage, D., Valckenborgh, E. V., Camp, B. V., Álvarez, E., & Vanderkerken, K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604388 · Cited by 40
Human AP endonuclease inefficiently removes abasic sites within G4 structures compared to duplex DNA
Broxson, C., Hayner, J. N., Beckett, J., Bloom, L. B., & Tornaletti, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku417 · Cited by 38
Zhao, S., Molina, A., Yu, A., Hanson, J., Cheung, H., Li, X., & Natkunam, Y. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.114 · Cited by 39
Awada, H., Thapa, B., Awada, H., Dong, J., Gurnari, C., Hari, P., & Dhakal, B. (2021) · Cells · doi:10.3390/cells10081961 · Cited by 35
ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells
Dhyani, A., Duarte, A. S. S., Machado‐Neto, J. A., Favaro, P. M. B., Ortega, M. M., & Saad, S. T. O. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.10.037 · Cited by 39
Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice
Landgren, O., & Morgan, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2159 · Cited by 38
Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa
Malacrida, A., Cavalloro, V., Martino, E., Cassetti, A., Nicolini, G., Rigolio, R., Cavaletti, G., Mannucci, B., Vasile, F., Giacomo, M. D., et al. (2019) · Molecules · doi:10.3390/molecules24132500 · Cited by 38
Cheong, C. M., Mrozik, K. M., Hewett, D. R., Bell, E., Panagopoulos, V., Noll, J. E., Licht, J. D., Gronthos, S., Zannettino, A. C. W., & Vandyke, K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.040 · Cited by 38
Chesi, M., Bergsagel, P. L., & Kuehl, W. M. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00005 · Cited by 38
Self-citationT HE B IOLOGY AND C YTOGENETICS OF M ULTIPLE M YELOMA
Ho, P. J., Campbell, L. J., Gibson, J., Brown, R. D., & Joshua, D. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00081.x · Cited by 37
The IgH 3′ regulatory region and its implication in lymphomagenesis
Vincent‐Fabert, C., Fiancette, R., Cogné, M., Pinaud, E., & Denizot, Y. (2010) · European Journal of Immunology · doi:10.1002/eji.201040778 · Cited by 36
Yamazaki, H., Shirakawa, K., Matsumoto, T., Hirabayashi, S., Murakawa, Y., Kobayashi, M., Sarca, A. D., Kazuma, Y., Matsui, H., Maruyama, W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43575-y · Cited by 36
Lu, G. G., Muddasani, R., Orlowski, R. Z., Abruzzo, L. V., Qazilbash, M. H., You, M. J., Wang, Y., Zhao, M., Chen, S., Glitza, I. C., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0209-oa · Cited by 36
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
Longo, J., Smirnov, P., Li, Z., Branchard, E., van Leeuwen, J. E., Licht, J. D., Haibe‐Kains, B., Andrews, D. W., Keats, J. J., Pugh, T. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0962-2 · Cited by 36
Molecular Pathogenesis of Multiple Myeloma
Tonon, G. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.004 · Cited by 36
Chang, H., Li, D., Zhuang, L., Nie, E., Bouman, D., Stewart, A. K., & Chun, K. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001638832 · Cited by 36
Bahjat, M., & Guikema, J. E. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091876 · Cited by 35
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
Bloedjes, T. A., de Wilde, G., & Guikema, J. E. J. (2021) · Cancers · doi:10.3390/cancers13030396 · Cited by 35
Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma
Fabris, S., Storlazzi, C. T., Baldini, L., Nobili, L., Lombardi, L., Maiolo, A. T., Rocchi, M., & Neri, A. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10211 · Cited by 35
Xie, Z., Gunaratne, J., Cheong, L. L., Liu, S. C., Koh, T. L., Huang, G., Blackstock, W. P., & Chng, W. J. (2013) · Oncotarget · doi:10.18632/oncotarget.1049 · Cited by 34
Sonoki, T., Willis, T. G., Oscier, D. G., Karran, E. L., Siebert, R., & Dyer, M. J. S. (2004) · Leukemia · doi:10.1038/sj.leu.2403500 · Cited by 34
Zeppa, P., Fernandez, L. V. S., Cozzolino, I., Ronga, V., Genesio, R., Salatiello, M., Picardi, M., Malapelle, U., Troncone, G., & Vigliar, E. (2012) · Cancer Cytopathology · doi:10.1002/cncy.21203 · Cited by 33
Wiedmeier, J. E., & Bergsagel, P. L. (2022) · Life · doi:10.3390/life12060812 · Cited by 33
Self-citationIshikawa, H., Tsuyama, N., Liu, S., Abroun, S., Li, F., Otsuyama, K., Xu, Z., Ma, Z., Maki, Y., Iqbal, M. S., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208782 · Cited by 33
Impaired NHEJ function in multiple myeloma
Yang, C., Betti, C. J., Singh, S., Toor, A. A., & Vaughan, A. T. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.10.019 · Cited by 33
Huang, S., Yao, M., Tang, J., Tsay, W., Lee, F.-Y., Liu, M.-C., Wang, C., Chen, Y., Shen, M., & Tien, H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi273 · Cited by 33
Identification of Cyclin D3 as a Direct Target of E2A Using DamID
Song, S., Cooperman, J., Letting, D. L., Blobel, G. A., & Choi, J. K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8790-8802.2004 · Cited by 33
Ishikawa, H., Tsuyama, N., Obata, M., & Kawano, M. M. (2006) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.46.55 · Cited by 32
Chang, H., WECHALEKAR, A., Li, L., & Reece, D. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00217-6 · Cited by 32
Epigenetic Modifiers in Normal and Malignant Hematopoiesis
Haladyna, J. N., Yamauchi, T., Neff, T., & Bernt, K. M. (2015) · Epigenomics · doi:10.2217/epi.14.88 · Cited by 31
Targeting RSK2 in human malignancies
Kang, S., & Chen, J. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.531013 · Cited by 31
Jiménez, C., Jara‐Acevedo, M., Corchete, L. A., Castillo, D., Ordóñez, G. R., Sarasquete, M. E., Puig, N., Martínez‐López, J., Prieto-Conde, I., García‐Álvarez, M., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.08.004 · Cited by 31
Zhou, L., Zhang, Y., Sampath, D., Leverson, J. D., Dai, Y., Kmieciak, M., Nguyen, M. H., Orlowski, R. Z., & Grant, S. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.432 · Cited by 30
Metadata
- Authors
- Bergsagel, P. L., & Kuehl, W. M.
- Affiliations
- Cornell University (US)
- National Cancer Institute (US)
- Corresponding author
- Bergsagel, P Leif
- ORCID
- Bergsagel, P Leif
- Venue
- Oncogene
- Published
- 2001-09-10
- Volume
- 20
- Issue
- 40
- Pages
- 5611-5622
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1977707370
- Cited by
- 478
- References
- 64
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 16 · 2022: 17 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 15 · 2016: 17 · 2015: 21 · 2014: 16 · 2013: 26 · 2012: 19
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, chromosomal translocation, immunoglobulin heavy chain locus, monoclonal gammopathy of undetermined significance, cyclin D1, cyclin D3, FGFR3, MMSET, c-Maf, c-Myc, somatic hypermutation, tumor progression, extramedullary myeloma
- MeSH terms
- Cell Line, Transformed, Chromosomes, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 16, Chromosomes, Human, Pair 4, Chromosomes, Human, Pair 6, Chromosomes, Human, Pair 8, Humans, Immunoglobulins, Models, Genetic, Multiple Myeloma, Phenotype, Translocation, Genetic, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.